Potential of Cationic Liposomes as Adjuvants/Delivery Systems for Tuberculosis Subunit Vaccines
The weakness of the BCG vaccine and its highly variable protective efficacy in controlling tuberculosis (TB) in different age groups as well as in different geographic areas has led to intense efforts towards the development and design of novel vaccines. Currently, there are several strategies to develop novel TB vaccines. Each strategy has its advantages and disadvantages. However, the most important of these strategies is the development of subunit vaccines. In recent years, the use of cationic liposome-based vaccines has been considered due to their capacity to elicit strong humoral and cellular immune responses against TB infections. In this review, we aim to evaluate the potential for cationic liposomes to be used as adjuvants/delivery systems for eliciting immune responses against TB subunit vaccines. The present review shows that cationic liposomes have extensive applications either as adjuvants or delivery systems, to promote immune responses against Mycobacterium tuberculosis (Mtb) subunit vaccines. To overcome several limitations of these particles, they were used in combination with other immunostimulatory factors such as TDB, MPL, TDM, and Poly I:C. Cationic liposomes can provide long-term storage of subunit TB vaccines at the injection site, confer strong electrostatic interactions with APCs, potentiate both humoral and cellular (CD4 and CD8) immune responses, and induce a strong memory response by the immune system. Therefore, cationic liposomes can increase the potential of different TB subunit vaccines by serving as adjuvants/delivery systems. These properties suggest the use of cationic liposomes to produce an efficient vaccine against TB infections.
KeywordsAdjuvant Cationic liposome Delivery system M. tuberculosis Subunit vaccine
No funding was received for preparing this review.
Compliance with Ethical Standards
This is a review article not involving any cellular, animal or human test.
Conflict of Interest
- Ahmaditabar P, Momtazi-Borojeni AA, Rezayan AH, Mahmoodi M, Sahebkar A, Mellat M (2017) Enhanced entrapment and improved in vitro controlled release of N-acetyl cysteine in hybrid PLGA/lecithin nanoparticles prepared using a nanoprecipitation/self-assembly method. J Cell Biochem 118(12):4203–4209CrossRefPubMedCentralPubMedGoogle Scholar
- Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A et al (2009) Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells. Vaccine 27:28–37CrossRefPubMedGoogle Scholar
- de la Torre LG, Rosada RS, Trombone APF, Frantz FG, Coelho-Castelo AA, Silva CL et al (2009) The synergy between structural stability and DNA-binding controls the antibody production in EPC/DOTAP/DOPE liposomes and DOTAP/DOPE lipoplexes. Colloids Surf B Biointerfaces 73:175–184CrossRefPubMedGoogle Scholar
- Fasihi-Ramandi M, Ghobadi-Ghadikolaee H, Ahmadi-Renani S, Taheri RA, Ahmadi K (2018) Vibrio cholerae lipopolysaccharide loaded chitosan nanoparticle could save life by induction of specific immunoglobulin isotype. Artif Cells Nanomed Biotechnol 46(1):56–61. https://doi.org/10.1080/21691401.2017.1290646CrossRefPubMedPubMedCentralGoogle Scholar
- Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P et al (2010a) Comparison of the depot effect and immunogenicity of liposomes based on dimethyldioctadecylammonium (DDA), 3β-[N-(N′, N′-dimethylaminoethane) carbomyl] cholesterol (DC-Chol), and 1, 2-dioleoyl-3-trimethylammonium propane (DOTAP): prolonged liposome retention mediates stronger Th1 responses. Mol Pharm 8:153–161CrossRefPubMedCentralPubMedGoogle Scholar
- Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P et al (2010b) Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 145:102–108CrossRefPubMedCentralPubMedGoogle Scholar
- Holten-Andersen L, Doherty T, Korsholm K, Andersen P (2004) Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun 72:1608–1617CrossRefPubMedCentralPubMedGoogle Scholar
- Karimi SM, Sankian M, Khademi F, Tafaghodi M (2016) Chitosan (CHT) and trimethylchitosan (TMC) nanoparticles as adjuvant/delivery system for parenteral and nasal immunization against Mycobacterium tuberculosis (MTb) ESAT-6 antigen. Nanomed J 3:223–229Google Scholar
- Khademi F, Derakhshan M, Sadeghi R (2016) The role of toll-like receptor gene polymorphisms in tuberculosis susceptibility: a systematic review and meta-analysis. Rev Clin Med 3:133–140Google Scholar
- Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL (2010) Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant. Clin Vaccine Immunol 17:793–801CrossRefPubMedCentralPubMedGoogle Scholar
- McNeil SE, Rosenkrands I, Agger EM, Andersen P, Perrie Y (2011) Subunit vaccines: distearoylphosphatidylcholine-based liposomes entrapping antigen offer a neutral alternative to dimethyldioctadecylammonium-based cationic liposomes as an adjuvant delivery system. J Pharm Sci 100:1856–1865CrossRefPubMedGoogle Scholar
- Mosavat A, Soleimanpour S, Farsiani H, Sadeghian H, Ghazvini K, Sankian M et al (2016) Fused Mycobacterium tuberculosis multi-stage immunogens with an Fc-delivery system as a promising approach for the development of a tuberculosis vaccine. Infect Genet Evol 39:163–172CrossRefPubMedCentralPubMedGoogle Scholar